Home › Trial NCT03450330
Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer
- Trial IDNCT03450330
- StatusCompleted
- PhasePhase 1/2
- Study typeInterventional
- SponsorDizal Pharmaceuticals
- Enrollment10
- Start date2018-04-16
- ConditionsNonsmall Cell Lung Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.